NCT Neuro Master Match - N²M² (NOA-20)

Phase 1/2 Completed 228 enrolled University Hospital Heidelberg German Cancer Aid · collab German Cancer Research Center · collab National Center for Tumor Diseases, Heidelberg · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of N²M² is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design. The progression-free survival rate at six months (PFS-6) will be used to make decisions.

Timeline

Start: 2018-05-07
Primary completion: 2023-02-22
Completion: 2023-02-22

Publications

Wick W, Lanz LM, Wick A, Harting I, Dettmer S, Suwala AK, Ketter R, Tabatabai G, Seliger C, Glas M, Burger MC, Timmer M, Ringel FA, Mildenberger I, Schulz-Schaeffer WJ, Winkler F, Konig L, Herold-Mende C, Eisenmenger A, Pfister SM, Renovanz M, Bendszus M, Sahm F, Platten M, Kessler T. Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial. Nat Med. 2025 Oct;31(10):3534-3541. doi: 10.1038/s41591-025-03928-9. Epub 2025 Sep 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Asunercept	Protein / enzyme biologic	800 mg	Intravenous
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Subject	Idasanutlin	Small molecule	100 mg	Oral
Subject	Palbociclib	Small molecule	75 mg	Oral
Subject	Palbociclib	Small molecule	100 mg	Oral
Subject	Palbociclib	Small molecule	125 mg	Oral
Subject	Temsirolimus	Small molecule	25 mg	Intravenous
Background	Alectinib	Small molecule	600 mg	Oral
Background	Vismodegib	Small molecule	150 mg	Oral

NCT Neuro Master Match - N²M² (NOA-20)

Summary

Timeline

Publications

Drugs

Indications